<DOC>
	<DOCNO>NCT01299298</DOCNO>
	<brief_summary>This Phase 1 study conduct evaluate 3 increase subcutaneous ( SC ) dose ( 50 , mg , 100 mg 200mg ) mipomersen Japanese healthy volunteer . Eligible subject receive single study injection either mipomersen placebo . Subjects enrol 1 3 treatment cohort ( Cohorts A , B , C ) dose-escalation design . Dose-escalation proceed acceptable safety profile previous dose level .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetics , Safety , Tolerability Single Doses Mipomersen Japanese Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Mipomersen</mesh_term>
	<criteria>First generation Japanese ( born Japan Japanese parent Japanese grandparent ) , live 5 year outside Japan , significant change lifestyle habit , include diet , live outside Japan . Surgically sterile , abstinent subject partner compliant acceptable contraceptive 24 week last study drug dose Body weight &gt; 50 kg body mass index 18 30 kg/m2 inclusive Clinically significant cardiovascular , pulmonary , hepatic , renal , haematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , infectious , psychiatric disease Clinically significant abnormal finding physical examination , ECG , blood pressure , heart rate , medical history , clinical laboratory result Screening dose Positive test human immunodeficiency virus ( HIV ) , hepatitis B C. High sensitivity Creactive protein ( hsCRP ) &gt; 5 mg/L History current malignancy ( exception basal squamous cell carcinoma skin adequately treat recurrence &gt; 1 year ) Evidence acute ongoing chronic inflammatory condition infection History rash , impetigo , drug allergy Alcohol and/or drug abuse Smoking 10 cigarette per day Planned dental work include Day 8 procedure Treatment another investigational drug , biological agent , device within 4 week Screening 5 halflives study agent , whichever long Use prescribe medication within 4 week overthe counter medication ( include dietary supplement herbal remedy ) within 14 day first study drug dose , use concomitant medication ( prescribed counter ) Day 8 study without Investigator Sponsor approval . Vaccinations allow begin 3 week prior first dose study drug completion safety followup period Previous exposure oligonucleotidebased drug therapy Donated 50 499 mL blood within 30 day prior consent , &gt; 499 mL within 60 day</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>